Abstract
Inadequate antiprotease activity in the lungs due to alpha-1-antitrypsin (A1AT) deficiency is a factor of early-onset emphysema. We propose a new approach to gene therapy that involves the intratracheal delivery of macrophages expressing human A1AT (hA1AT). Recombinant adeno-associated virus (rAAV) plasmids encoding the hA1AT gene were packaged into virions using 293 cells, and transgenic progeny virus was purified from the cells. The murine macrophage cell line J774A.1 was infected in vitro with the recombinant hA1AT rAAV virus. The hA1AT-producing macrophages were delivered intratracheally into mechanically ventilated C57BL/6J mice, a strain with low endogenous levels of A1AT. Transcription of hA1AT mRNA was detected in the transfected cells by RT-PCR, and protein expression was verified by immunohistochemistry. Levels of hA1AT in the cell culture medium and in the bronchoalveolar lavage (BAL) were assayed by ELISA. The concentration of hA1AT in J774A.1 cell-conditioned medium increased from undetectable levels prior to transfection, to 60 mg/l at 24 h post-transfection. At 1, 3 and 7 days after intratracheal delivery of transfected macrophages, hA1AT protein in BAL from C57BL/6J mice increased from undetectable levels to 2.5±0.9, 2.6±1.1 and 2.2±0.8 mg/l, respectively. These results suggest that airway delivery of macrophages overexpressing hA1AT may be an effective approach to enhance alveolar protection in A1AT deficiency.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carrell RW, Lomas DA . Alpha1-antitrypsin deficiency – a model for conformational diseases. N Engl J Med 2002; 346: 45–53.
Coakley RJ, Taggart C, O'Neill S, McElvaney NG . Alpha1-antitrypsin deficiency: biological answers to clinical questions. Am J Med Sci 2001; 321: 33–41.
Wencker M, Fuhrmann B, Banik N, Konietzko N . Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119: 737–744.
Mullins CD, Huang X, Merchant S, Stoller JK . The direct medical costs of alpha(1)-antitrypsin deficiency. Chest 2001; 119: 745–752.
Dasi F et al. Asialofetuin liposome-mediated human alpha1-antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med 2001; 79: 205–212.
Rosenfeld MA et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252: 431–434.
Kay MA, Graham F, Leland F, Woo SL . Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 1995; 21: 815–819.
Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet 1995; 11: 191–197.
Setoguchi Y, Jaffe HA, Chu CS, Crystal RG . Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 1994; 10: 369–377.
Levy MY, Barron LG, Meyer KB, Szoka Jr FC . Characterization of plasmid DNA transfer into mouse skeletal muscle: evaluation of uptake mechanism, expression and secretion of gene products into blood. Gene Therapy 1996; 3: 201–211.
Schiedner G et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180–183.
Morral N et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9: 2709–2716.
Xiao X, Li J, Samulski RJ . Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098–8108.
Flotte TR et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993; 90: 10613–10617.
Jooss K, Yang Y, Fisher KJ, Wilson JM . Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212–4223.
Flotte TR, Laube BL . Gene therapy in cystic fibrosis. Chest 2001; 120: 124S–131S.
Song S et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Therapy 2001; 8: 1299–1306.
Song S et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95: 14384–14388.
Stecenko AA, Brigham KL . Gene therapy progress and prospects: alpha-1 antitrypsin. Gene Therapy 2003; 10: 95–99.
Gill DR et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Therapy 2001; 8: 1539–1546.
Wu M et al. Genetically engineered macrophages expressing IFN-gamma restore alveolar immune function in scid mice. Proc Natl Acad Sci USA 2001; 98: 14589–14594.
Xiao W et al. Adeno-associated virus as a vector for liver-directed gene therapy. J Virol 1998; 72: 10222–10226.
Collaco RF, Cao X, Trempe JP . A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999; 238: 397–405.
Gardi C et al. Neutrophil lysosomal dysfunctions in mutant C57 Bl/6J mice: interstrain variations in content of lysosomal elastase, cathepsin G and their inhibitors. Biochem J 1994; 299 (Part 1): 237–245.
Rennard SI et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986; 60: 532–538.
Wewers MD et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 1055–1062.
Gadek JE et al. Danazol-induced augmentation of serum alpha-1-antitrypsin levels in individuals with marked deficiency of this antiprotease. J Clin Invest 1980; 66: 82–87.
Wewers MD et al. Evaluation of danazol therapy for patients with PiZZ alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1986; 134: 476–480.
Schwaiblmair M, Vogelmeier C, Fruhmann G . Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency – three-year follow-up. Respiration 1997; 64: 10–15.
Yuan ZA, Soprano KJ, Kueppers F . Alpha-1 antitrypsin response of stimulated alveolar macrophages. J Cell Biochem 1992; 49: 410–416.
Hu C, Perlmutter DH . Cell-specific involvement of HNF-1beta in alpha(1)-antitrypsin gene expression in human respiratory epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002; 282: L757–765.
Cichy J, Potempa J, Travis J . Biosynthesis of alpha1-proteinase inhibitor by human lung-derived epithelial cells. J Biol Chem 1997; 272: 8250–8255.
Crystal RG . Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990; 85: 1343–1352.
Vogelmeier C et al. The intrapulmonary half-life and safety of aerosolized alpha1-protease inhibitor in normal volunteers. Am J Respir Crit Care Med 1997; 155: 536–541.
Kropp J et al. Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency? J Nucl Med 2001; 42: 744–751.
Dhami R et al. Pulmonary epithelial expression of human alpha1-antitrypsin in transgenic mice results in delivery of alpha1-antitrypsin protein to the interstitium. J Mol Med 1999; 77: 377–385.
Pasula R, Weaver T, Martinez MA, Martin II WJ . Morphologic detection and functional assessment of reconstituted normal alveolar macrophages in the lungs of SCID mice. J Immunol 2002; 169: 4504–4510.
Acknowledgements
This research was supported in part by the National Institute of Health (R01 AI48455).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhang, D., Wu, M., Nelson, D. et al. Alpha-1-antitrypsin expression in the lung is increased by airway delivery of gene-transfected macrophages. Gene Ther 10, 2148–2152 (2003). https://doi.org/10.1038/sj.gt.3302121
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302121
Keywords
This article is cited by
-
Pulmonary transplantation of alpha-1 antitrypsin (AAT)-transgenic macrophages provides a source of functional human AAT in vivo
Gene Therapy (2021)
-
Pseudomonas aeruginosa infection augments inflammation through miR-301b repression of c-Myb-mediated immune activation and infiltration
Nature Microbiology (2016)
-
High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques
Medical Oncology (2013)